Skip to content Skip to sidebar Skip to footer

U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD

Non-Invasive, Self-Neuromodulation, Adjunct to Standard of Care Therapy Using Amygdala Derived EEG-fMRI Pattern Biomarkers to Help Patients with PTSD HAIFA, Israel – March 21, 2023 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its flagship…

Read More

GrayMatters Health Receives Investment from European Innovation Council (EIC) Fund

Just Six Months After Awarding GrayMatters Health a Grant of €2.5M, the EIC Demonstrates Vote of Confidence with Equity Investment in the Company HAIFA, Israel – March 20, 2023 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, announced today that the European Innovation Council (EIC) Fund, following the September 2022 grant…

Read More

GrayMatters Health Awarded €2.5M in Funding from European Innovation Council

HAIFA, Israel – September 7, 2022 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, has been awarded a €2.5 million grant from the European Innovation Council (EIC) to accelerate the development of Prism for PTSD, a non-invasive digital therapy, to be used as an adjunct to standard of care (SOC) treatments…

Read More

GrayMatters Health Closes $10M Round A Funding and Partnership in Japan

Investment Led by Otsuka Medical Devices HAIFA, Israel, Jan. 11, 2022 /PRNewswire/ -- GrayMatters Health (GMH) developer of digital self-neuromodulation therapeutics for mental disorders, announced today the successful closing of its $10 million Series A financing round. Otsuka Medical Devices Co., Ltd. (OMD) was the lead investor in this round. In addition to its investment, OMD obtained certain rights with regard…

Read More